Fig. 1.

Median pazopanib, gemcitabine, and dFdU concentration–time profiles from patients in the cohort-expansion phase: gemcitabine (1,250 mg/m² by 30-min infusion) was administered alone on Cycle 1 Day 1 (C1D1) and in combination with oral pazopanib (800 mg) on Cycle 2 Day 1 (C2D1); pazopanib was administered once daily beginning on C1D2, and gemcitabine was administered on Days 1 and 8 of the 21-day cycle